RxAmerica and Accendo Insurance notify 175,000 Medicare beneficiaries that mailing error exposed their medication name, date of birth, and member ID
RxAmerica and Accendo Insurance Company, providers of drug benefits to eligible beneficiaries under the Medicare Part D program, issued the following statement today regarding a recent patient information issue:
“RxAmerica and Accendo Insurance Company have notified Medicare Part D beneficiaries enrolled in the company’s Prescription Drug Plans that some of their personal information may have been exposed during recent mailings of transition fill letters to physicians. While the mailings were addressed correctly and, to the knowledge of the company, were received by the intended recipients, a formatting change shifted the text of the letters, allowing some lines of text to be visible through the envelope window.
“The personal information that may have been exposed in the envelope window of the letters included the member’s name and some combination of member ID number, drug name and date of birth. Approximately 175,000 members were affected. No other information was at risk, and there is no evidence that any of this information was used improperly.
“RxAmerica and Accendo Insurance Company place the highest priority on protecting the privacy of its customers and plan members, and are working diligently to improve procedures, policies and technology to ensure this type of incident does not recur. Nothing is more central to our health care operations than maintaining the privacy of our customers’ personal information. We have corrected the problem surrounding the letter in question and, out of an abundance of caution, are offering affected members credit monitoring, fraud and identity theft counseling services through one of the major credit bureaus, at no cost, for one year. Each affected plan member will be receiving a communication outlining these services and how to use them.”
Accendo Insurance Company, operated by RxAmerica, both of which are subsidiaries of CVS Caremark, provides drug benefits to eligible beneficiaries under the Federal Government’s Medicare Part D program. RxAmerica has been offering Part D plans since the program’s inception in 2006.